CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Remimazolamdrug
Likely dose
Remimazolam 0.075 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05760534
NCT05760534Phase 4Completed
CompareCT.gov

Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia - a Phase 4 Clinical Trial

Seoul National University Hospital·interventional·Posted Mar 8, 2023·Updated Dec 29, 2025

In Brief

A Phase 4 clinical trial evaluating Remimazolam for Arthritis Knee and Arthritis Hip. Completed, enrolled 110 participants across 1 site.

Detailed Summary

This study aims to compare ideal body weight- and total body weight-based dosage for remimazolam sedation of obese patients undergoing knee or hip arthroplasty under spinal anesthesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis Knee, Arthritis Hip
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMar 8, 2023
Enrollment StartMar 6, 2023
Primary CompletionNov 25, 2025
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 3.3 years ago

Interventions

Remimazolamdrug

0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight